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Abstract
Background: Surveillance magnetic resonance imaging (MRI) is routinely used to detect recur-
rence in children with high-grade central nervous system (CNS) tumors, although no consen-
sus has been reached regarding its effectiveness and whether earlier detection is associated
with improved patient outcomes. This review aimed to evaluate this practice and any associated
benefits and harms.
Methods: Systematic searches for relevant studies were undertaken in a number of databases,
includingMEDLINE and EMBASE, from1985 toAugust 2018. Study selection and data extraction
was undertaken independently by two reviewers. Due to heterogeneity between studies, no pool-
ingof datawasundertaken. Reporting followedPreferredReporting Items for SystematicReviews
andMeta-Analyses (PRISMA) guidelines.
Results: No comparative studies were identified. Three retrospective observational studies
involving 306 patients were reviewed. All had high risk of bias by virtue of study design. Two
studies reported outcomes by symptomatic status—both recurrence rates and overall survival
for asymptomatic patients were comparable with those for clinically symptomatic patients. No
quality-of-life outcomes were reported.
Conclusion: There is a paucity of evidence to guide clinical practice as to the effectiveness of
MRI surveillance in pediatric patients with high-grade CNS tumors. These studies do not clearly
demonstrate benefit or harm for the practice. With more research needed, there is a role for
researchers to build into future trials data collection on surveillance imaging to give more infor-
mation for the assessment of imaging frequency and duration in asymptomatic patients. This is
an important question not only to clinicians and patients and their families but also from a health
service resource perspective.
K EYWORDS
high-grade tumors, magnetic resonance imaging (MRI), pediatric CNS tumors, recurrence,
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1 INTRODUCTION
Pediatric high-grade central nervous system (CNS) tumors are
fast-growing, malignant tumors with metastatic potential and are
commonly associatedwithpoorprognosis evenaftermultimodal treat-
ment. Generally classified by the World Health Organisation (WHO)
as either grade III or IV tumors, they include glial (anaplastic astrocy-
toma and glioblastoma multiforme), ependymal (ependymoma, both
WHO grade II and III), and embryonal (medulloblastoma and tumors
previously known as primitive neuroectodermal tumors (PNET))
tumors, as well as brainstem tumors (diffuse pontine glioma (DIPG)),
atypical teratoid/rhabdoid tumor (AT/RT), and pineoblastoma. Many
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children with high-grade CNS tumors will go on to experience recur-
rence or progression, and the likelihood of this will depend on the
histology and location of their first tumor, as well as treatments
given.1,2
In recent years, magnetic resonance imaging (MRI) has become the
predominant imaging tool in the management of children with high-
grade CNS tumors. The rationale behind routine imaging, or surveil-
lance, is that recurrence or progressive disease detected at an earlier
stage may be more responsive to treatment and benefit from a wider
rangeof treatmentoptions thandiseasediagnosedat a later stage from
clinical signs and symptoms. However, no consensus has been reached
as to whether this leads to improved outcomes for patients and their
families.
The objectives of this reviewwere therefore to:
1. assess the diagnostic utility of surveillance MRI in detecting tumor
recurrence prior to the emergence of new clinical signs and symp-
toms comparedwith the non-routine use ofMRI upon symptomatic
presentationandassesswhether this practice translates tomeasur-
able improvements in clinical outcomes;
2. consider the effect of differing screening intervals on thediagnostic
utility of surveillance MRI and determine the optimal duration of
imaging after initial diagnosis; and
3. identify any gaps and methodological weaknesses in the current
evidence base and make recommendations to inform the design
and analysis of future studies.
The authors have also undertaken a systematic review on the effec-
tiveness of surveillance MRI in pediatric low-grade tumors, which
forms a companion piece to this review paper.3
2 METHODS
Standard systematic review methodology was employed and report-
ing followed the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines.4 A detailed account of the
methodology employed in this review can be found in the pub-
lished protocol, which is also registered with PROSPERO (CRD
42016036802).5 A summary of themethods is described below.
2.1 Search strategy
This review formed part of a wider NIHR-funded work program of
systematic reviews aimed at assessing the effects of different inter-
ventions for the treatment of pediatric CNS tumors and therefore
searches were not restricted to studies concerned solely with surveil-
lance imaging in children with high-grade tumors. Searches for pub-
lished studies from 1985 to August 2018 were undertaken in several
databases, including MEDLINE and EMBASE (see Supporting Infor-
mation File S1). No language, publication restrictions, or study design
filters were applied.
2.2 Study selection
The following inclusion and exclusion criteria were applied:
Population: Children and young adults (up to age 25 years) with diag-
noses of any type of high-grade CNS tumor who were asymptomatic
at the time of study recruitment. Given that children undergoing
surveillance may have some neurologic sequelae from their tumor
and/or its treatment, it would be more accurate to characterize
patients as exhibiting no new, stable, or improved neurological signs
or symptoms.
Interventions: Routine or surveillance MRI. Studies employing com-
puted tomography (CT) as the sole surveillance imaging modality
were excluded.
Outcomemeasures: These included recurrence rates (by study, tumor
type, location, and extent of resection), diagnostic yield of imaging,
timing of recurrence, change in patientmanagement postrecurrence,
overall survival (OS), surrogate survival measures (e.g., recurrence-
free survival, progression-free survival (PFS)), and quality of survival.
Studies reporting outcomes fromaggregatedCT andMRI scanswere
excluded.
Studydesigns: As randomized controlled trials (RCTs) andnonrandom-
ized comparative studies were initially sought but not identified, the
review was extended to include observational studies such as case
series.
Study selection was undertaken by two independent reviewers,
with disagreements resolved by discussion.
2.3 Data extraction and risk of bias assessment
Data, extracted by one reviewer and checked by a second, were
recorded on a standardized proforma developed in Microsoft Word
(see Supporting Information File S2). Risk of bias was assessed at
the study level by two reviewers using a six-point tool devised by
the Centre for Reviews and Dissemination (York; CRD)6 designed to
assess bias in case series studies.
2.4 Statistical analysis
Due to the design of the included studies and the heterogeneity of out-
comes reported, only a descriptive analysis was undertaken.
3 RESULTS
3.1 Quantity and description of included studies
From the electronic database searches, 28 potentially relevant publi-
cations were identified, with an additional 13 publications identified
from citation-checking. On full-text examination, 38 were excluded,
including 11 studies that employed both CT and MRI as surveillance
imaging modalities but failed to report results separately for MRI (see
Supporting Information File S3). No RCTs or prospective compara-
tive studies were identified. Three retrospective case series studies7–9
were included in the review (see Figure 1).
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F IGURE 1 PRISMA diagram of flow of studies through the selection
process
The three studies were conducted between 2001 and 2014
and undertaken at single-center institutions. Two studies8,9 included
patients with high-grade tumors only, with one7 including amix of low-
and high-grade tumor patients (see Table 1).
3.2 Quality of the research
Studies were clinically heterogeneous with study populations varying
in terms of both tumor type and disease severity. Study samples were
small but patients appeared to be representative of the target popula-
tion, although it was unclear whether patients were at a similar time
point in the disease progression. Inclusion and exclusion criteria for
each study were explicitly stated. Generally, details of previous treat-
ments were not reported (see Supporting Information File S4). There
was also variability in terms of reporting and defining of outcomes. The
terms “recurrence” and “progression” were defined in all three studies,
althoughonly two reported recurrences as “symptomatic” and “asymp-
tomatic” and defined these terms.7,9 All three studies reported OS,
although only Kornreich8 defined the term (see Supporting Informa-
tion Table S5). This was also the only study to report PFS. Korones7 did
not report average duration of follow-up.
3.3 Included studies
3.3.1 Korones (2001)7
Korones7 was a mixed tumor grade study with 112 children at study
commencement. Patient details were provided only for the 46 patients
who went on to experience recurrence/progression. Of these, 33 had
high-grade tumors. Eight tumor types were included. The median age
of thesepatients at recurrencewas six years (range, 0.25–21), although
this was not reported by tumor type.
All patients underwent surgery as the primary treatment, although
this was not further specified by extent of resection (i.e., gross total
resection (GTR) vs subtotal resection (STR)). At the commencement of
surveillance imaging, none of the patients had relapsed disease.
With respect to imaging frequency, patients received a median of
one scan every 2.5 months (range, 1/1 to 1/6.7 months) irrespective of
whether they were symptomatic or asymptomatic at recurrence. Fre-
quency of scanning was not reported by tumor type.
As only data on recurrent patients were reported, it was not
possible to calculate the recurrence rate for the 33 high-grade
tumor patients as a whole, nor by tumor type. The rate of recur-
rence/progression by symptomatic status was reported, with 17
patients (52%) asymptomatic at recurrence. Recurrence by symp-
tomatic status was also reported by tumor type, with asymptomatic
and symptomatic recurrences comparable in number, although the
numbers in each category were very small (ranging from 1 to 6) (see
Table 2). Recurrence by extent of resection was not reported.
Thediagnostic yield of imaging for all 17 asymptomatic patientswas
4.4%, i.e., one asymptomatic recurrence detected every 23 MRI scans
(see Table 2). With respect to choroid plexus carcinoma (CPC), germ
cell tumor (GCT), and AT/RT, there were two asymptomatic recur-
rences among these tumor types, and the diagnostic yield of imaging
was 6.5%.
The median time to recurrence from initial diagnosis for all
33 patients was 0.75 years, with no significant difference in median
time to recurrence between symptomatic and asymptomatic patients
at recurrence (0.66 and 0.77 years, respectively). The median time to
recurrencewas not reported by individual tumor type, nor by extent of
resection.
Information regarding local therapy received following recur-
rence/progression was provided for 26 patients (79%), with 8 of 14
asymptomatic patients (57%) undergoing local therapy (surgery with
or without stereotactic radiosurgery) compared with only 3 of 12
symptomatic patients (25%) (P = 0.13). Again, change in patient man-
agement was not reported by tumor type.
Overall survival from recurrence for all 33 patients was reported
but only by symptomatic status at recurrence, with median OS for
the 17 asymptomatic patients (0.58 years) marginally and nonsta-
tistically significantly greater (P = 0.25) than that for the 16 symp-
tomatic patients (0.42 years). Median OS was not reported by tumor
type.
3.3.2 Kornreich (2005)8
Kornreich8 was a retrospective case series study looking at the role
of surveillance MRI in the management of 15 pediatric patients with
DIPG. Although the frequency of imaging was not reported, the mean
number ofMRI scans per patientwas six. Thirteenpatients (87%) expe-
rienced tumor progression, while two patients remained stable. Symp-
tomatic status of patients at progression was not reported.
Median PFS was 0.83 years, ranging from zero months (in four
patients who deteriorated immediately from diagnosis without any
prior period of stability) to nine years. Treatment (radiotherapy and/or
chemotherapy)was planned and not consequent to changes in scans or
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TABLE 1 Characteristics of included studies
Study (year) (ref)
Location
Years of study
Aim
Study design Population Intervention Outcomes reported
Korones et al
(2001)7
USA
1990–1999
To determine the
frequency of
detection of recur-
rent/progressive
brain tumors in
asymptomatic
children are
detected by
surveillanceMRI
scans and to
compare the
survival of children
with asymptomatic
recurrence
comparedwith
those whose
recurrences are
detected by
symptoms
Retrospective case
series study
Included: Patients with a brain
tumor aged<21 at diagnosis and
for whom neuroimaging
surveillance was performed
exclusively byMRI.
Excluded: Patients with spinal cord
tumors or children followed by CT
scans.
Tumor type: Both low- and
high-grade tumors, including 33
(72%) recurrent high-grade tumors
including:
- HGG (anaplastic astrocytoma,
glioblastomamultiforme):
n= 10 (30%)
- Brainstem glioma: n= 7 (21%)
- sPNET: n= 5 (16%)
- MB: n= 4 (12%)
- Epend: n= 4 (12%)
- CPC: n= 1 (3%)
- GCT: n= 1 (3%)
- AT/RT: n= 1 (3%)
N= 112 (although the paper focuses
exclusively on the 46 recurrent
patients)
Male: 45%
Median age at diagnosis (n= 46):
6.5 years (0.25–21)
Median age at recurrence for 33
high-grade patients: 6 years
(0.25–21)
Average follow-up: NR
Tumor location: NR
Previous treatment(s):
- Surgery: n=NR
SurveillanceMRI.
Details:
• MRI scanner: No details.
• Image sequences taken:
No details.
• Imaging schedule:
1 scan every 2.5months
(range, 1/1month to
1/6.7months).
• Average number ofMRI
images per patient:
NR for high-grade tumor
patients only.
SurveillanceMRI: “Scans done
≥1month after surgery
(or>1month after the
original diagnosticMRI if
diagnosis was byMRI only)
were considered
surveillance scans.
Immediate postoperative
MRI scans were not
considered surveillance
scans.”
• Recurrence by symptomatic
status
• Median time from diagnosis to
recurrence by tumor grade
• MedianOS by symptomatic status
for all patients
• MedianOS for symptomatic
status for high-grade tumor
patients
• Overall survival (n= 46)
• 2-year OS from time of
recurrence by symptomatic status
Kornreich et al
(2005)8 Israel
1985–2001
To describe theMR
findings of pontine
tumors at diagnosis
and during
follow-up and
correlate those
with prognosis and
to assess the value
ofMR imaging in
patient
management
comparedwith
clinical evaluation.
Retrospective case
series study
Included: Patients with a DIPG
“according to the classification of
Barkovich et al (center of themass
in the pons, involving>50% of the
axial area) who underwentMR
imaging at diagnosis and at least
once during treatment.”
Excluded: NR
Tumor grade: only pathologically
confirmable in the 3 patients who
underwent surgery at diagnosis:
- glioblastomamultiforme (n= 1)
- astrocytoma grade II (n= 1)
- astrocytoma grade III (n= 1)
Tumor location: “center of themass
in the pons, involving> 50% of the
axial area”
N= 15
Male: 73%
Median age at diagnosis: 5.6 years
(range, 2–19)
Average follow-up:
- Median: 1.5 yearsa (range,
0.17–9)
- Mean: 2.17 years
Previous treatment(s):
- Surgery (n= 3 patients with a
posterior cystic exophytic
component underwent
surgery at diagnosis)
SurveillanceMRI
Details:
• MRI scanner: No details.
• Image sequences taken: All
patients underwent at
least T1-weighted (T1W)
sagittal and T1Wand T2W
axial sequences, with
contrast agent
(gadopentate
dimeglumine) used in all
cases.
• Progression rate
• Medium time to progression
• MedianOS
• Median PFS
• Tumor response rates
• Changes in patient treatment due
to progression
(Continues)
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TABLE 1 (Continued)
Study (year) (ref)
Location
Years of study
Aim
Study design Population Intervention Outcomes reported
Perreault et al
(2014)9
USA
2000–2011
To assess the benefits
of surveillanceMRI
andmore
specifically spine
MRI in a
contemporary
cohort.
Retrospective case
series study
Included: Patients “with at least one
surveillanceMRI following the
diagnosis ofMB, ATRT, PB, (s)PNET,
(s)HGG (WHOgrades III and IV),
CNSGCT or Epend.”
Excluded: Patients with “a malignant
CNS tumor involving only the spine
at diagnosis.”
N= 258
Male: 62%
Median age at diagnosis: 8 years
(range, 0.3–21)
Median follow-up (n= 258): 3.12 years
(range, 0.13–11.8)
Tumor type(s): Mixed:
- MB: n= 89 (35%)
- AT/RT: n= 10 (4%)
- PB: n= 9 (3%)
- sPNET: n= 25 (10%)
- HGG: n= 34 (13%)
- GCT: n= 39 (15%)
- Ependymoma: n= 52 (20%)
Tumor grade:
- HGG:WHOgrade III–IV
- GCT:WHOgrades II and III
- Epend:WHO grades II and III
Tumor location: Supratentorial
(reported for PNET andHGGonly)
Previous treatment(s): NR
SurveillanceMRI.
Details:
• No details of theMRI
scanner used or the image
sequences taken.
• Median follow-up; total and by
tumor type
• Median number of scans (range);
total and by tumor type
• Recurrence rate; total and by
tumor type, and by first and
subsequent recurrences
• Symptomatic status at recurrence
• Median time to recurrence; total
and by tumor type, and by
symptomatic status at recurrence
• MedianOS by symptomatic status
at recurrence
• Frequency ofMRI-detected
recurrence; total and by tumor
type
• Changes in patient treatment due
to recurrence after first relapse
Abbreviations: AT/RT, atypical teratoid/rhabdoid tumor; CPC, choroid plexus carcinoma; DIPG, diffuse pontine glioma; Epend, ependymoma; GCT, germ cell
tumor;HGG, high-grade glioma;MB,medulloblastoma;MRI,magnetic resonance imaging; PB, pineoblastoma;N, number of patients;N/A, not applicable;ND,
not defined; NR, not reported; (s)HGG, (supratentorial) high-grade glioma; (s)PNET, (supratentorial) primitive neuroectodermal tumor;WHO:World Health
Organization.
aNot directly reported by the authors but calculated by the reviewer based on data reported in the publication.
TABLE 2 Summary of radiographic outcomes by tumor type for 33 high-grade tumor patients in Korones7
Patients with
recurrent
disease n (%)
Median time to recurrence in
years (range)
Tumor
type
N (recurrent
patients
only)
Median frequency
of imaging inmonths
(range) Asymp Symp
Diagnostic yield
ofMRIc (%)
Median time to
recurrence in
years (range) Asymp Symp
Total 33 1 scan/2.5 (1/1–1/6.7) 17 (52) 16 (48) 4.4 (656 scans) 0.75 (0.17–6) 0.75 (0.17–4.33) 0.67 (0.17–6)
HGG 10 NR 4 (40) 6 (60) 6.3 (63 scans) NR NR NR
DIPG 7 NR 3 (43) 4 (57) 15.3 (19 scans) NR NR NR
sPNETa 5 NR 3 (60) 2 (40) 7.2 (42 scans) NR NR NR
MB 4 NR 2 (50) 2 (50) 1.4 (147 scans) NR NR NR
Epend 4 NR 3 (75) 1 (25) 3.5 (86 scans) NR NR NR
Otherb 3 NR 2 (67) 1 (33) 6.5 (31 scans) NR NR NR
Abbreviations: asymp, asymptomatic; DIPG, diffuse pontine glioma; epend, ependymoma; GCT, germ cell tumor; HGG, high-grade glioma; MB, medulloblas-
toma;N, number of patients; sPNET, supratentorial primitive neuroectodermal tumor; symp, symptomatic.
aAs of 2016, the term PNET no longer appears in the currentWHO classification of CNS tumors.
b“Other” includes choroid plexus carcinoma (n= 1), germ cell tumor (n= 1), and atypical teratoid/rhabdoid tumor (n= 1).
cAsymptomatic recurrence only.
recurrence. MedianOSwas 1.67 years, with three patients (20%) alive
at the time of reporting.
3.3.3 Perreault (2014)9
Perreault9 was a retrospective case series study that sought to assess
the benefits of surveillance MRI in a cohort of 258 high-grade tumor
patients. Seven tumor types were included (see Table 1). All patients
underwent surgery as the primary treatment, although this was not
further specified by extent of resection. At commencement of surveil-
lance imaging, none of the patients had relapsed disease.
Although frequency of scanning was not reported, the median
number of MRI scans per patient across all tumor types was
6 of 9 STEVENS ET AL.
13, 10 of the brain and three spinal (see Table 3). The inter-
val since last MRI for symptomatic patients was not longer for
symptomatic compared with asymptomatic patients (mean, 3.9 vs
4.8months).
Rates of recurrence/progression were also reported by symp-
tomatic status (see Table 3). With respect to first recurrences
(n = 113), there was a slight predominance of asymptomatic (46%)
compared with symptomatic recurrences (42%), whereas for subse-
quent recurrences (n = 125) the converse was the case (29% vs 58%).
Recurrences (both first and subsequent) by symptomatic status were
also reported by tumor type where, in the case of medulloblastoma
and ependymoma, this trend continued with the majority of first
recurrences asymptomatic and second symptomatic. Conversely,
for supratentorial primitive neuroectodermal tumor (sPNET), the
majority of first recurrences were symptomatic and second asymp-
tomatic. For HGG, the majority of both first and second recurrences
were symptomatic. For the remaining tumor types (GCT, AT/RT,
and pineoblastoma), the number of recurrences was so small that
caution should be exercised when comparing recurrences by symp-
tomatic status (most notably AT/RT, with 100% of first recurrences
asymptomatic based on only four patients). Recurrences among
glioma patients were more frequently symptomatic compared with
those patients with other tumor types (68% vs 38%, respectively;
P = 0.003). The rate of recurrence by extent of resection was not
reported.
A breakdown of MRI scans by both tumor type and site of imaging
was reported, with diagnostic yield across all tumor types of 8.3% for
brain recurrence only (range, 2.1%–21.6%), 3.8% for combined brain–
spine recurrence (range, 1.6%–19.7%), and 0.9% for spine recurrence
only (range, 0.7%–4.9%) (see Table 3).
The median time to recurrence from initial diagnosis was 1 year,
although it is unclear whether this relates to first recurrence or
all recurrences. The median time to recurrence by tumor type was
reported but, again, it is unclear if this relates to first recurrence
or all recurrences (see Table 3). No significant difference in median
time to recurrence was reported between symptomatic and asymp-
tomatic patients at recurrence (1.0 and 0.92 years, respectively;
P > 0.8). The time by which greater than 90% of recurrences had
occurred for each individual tumor type was also reported (see
Table 3). Median time to recurrence by extent of resection was not
reported.
Change in patient management following first recurrence was
reported for 93% of patients, with 59% of patients undergoing new
treatments, 11% continuing with existing treatment, 16% scheduled
for palliative care, and 7% undergoing closer interval surveillance
MRI. New treatments consisted of chemotherapy (22% standard dose
and 4% high dose with stem cell support), radiotherapy (6%), radio-
surgery (2%), surgery (5%), and unspecified multimodal therapy (20%).
Change in patient management postrecurrence by tumor typewas not
reported.
There was no significant difference (P > 0.3) in median OS from
recurrence between symptomatic and asymptomatic patients (1.92
and 2.25 years, respectively). Median OS by tumor type was not
reported. T
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4 DISCUSSION
This systematic review is one of a series evaluating treatments for chil-
dren with CNS tumors. Underpinning the reviews was consultation
with clinical experts and a patient and public involvement (PPI) group,
consisting of mothers of children with CNS tumors. The PPI group in
particular expressed concerns about overscanning, especially in situ-
ations where scanning is no longer able to influence prognosis as in
the case of patients for which nothing further can be clinically done.
As well as the unknown risks associated with repeated administration
of contrast materials such as gadolinium,10 anesthesia, and sedatives,
the PPI group spoke of what has come to be termed “scanxiety,” i.e., an
overwhelming feeling of stress experienced by both patient and family
around the time of scanning. As one parent put it: “At times, it seems
like life and all its decisions revolve around scanning, which serves as
a constant reminder of the cancer and acts as an obstacle to resuming
normal behaviour.”
Although the use of surveillance MRI is standard practice through-
out the developed world in the management of children with high-
grade CNS tumors, this systematic review did not identify any RCTs
evaluating this intervention. After excluding 11 high-grade tumor
surveillance imaging studies which employed both CT and MRI but
did not report results separately by imaging modality,11–21 the review
included three retrospective, single-arm studies (n = 306 patients)
with MRI employed as the sole imaging modality. It could be argued
that in excluding studies employing CT imaging, the review has lost
valuable data on surveillance. However, the reason for focusing on
MRI, other than its superior sensitivity, is that MRI studies are more
recent than CT studies and therefore encompass an era of improved
survival and greater salvageability of patients due to improved
treatments.
The findings of the review were mixed. Korones7 concluded that
“asymptomatic recurrences were detected in only a small proportion
of surveillance scans and had no impact on survival in children with
high-grade tumours.” Kornreich8 reported on 15 patients with DIPG
and compared the findings of 51 surveillance scans with those from
clinical examination and reported a high degree of concordance (87%),
suggesting that for DIPG, surveillance MRI is providing little infor-
mation over and above that conveyed by clinical symptoms and signs
and therefore its utility may be limited. Ultimately, surveillance imag-
ing did not affect the treatment given, nor the outcome. On the basis
of this evidence, it could be argued, albeit tentatively, that certain
tumor types may be more amenable to surveillance MRI than oth-
ers and that for aggressive tumors such as DIPG, where often any
period of clinical stability is extremely limited, there is a very short
window of opportunity for surveillance imaging to exploit. In support
of this, Kornreich8 reported four patients with zero time to progres-
sion. However, with other, less aggressive high-grade tumor types, the
use of MRI surveillance may be of value. For example, with Perreault,9
asymptomatic recurrence rates were higher for ependymoma and
medulloblastoma compared with other tumor types, suggesting that
surveillancemight potentially be beneficial to these patients, although
in this study asymptomatic patients across all tumor types did not
benefit from improved OS compared with symptomatic patients.
Unfortunately, the potential for bias within case series is considerable,
and therefore conclusions from this review are tentative and should be
viewedwith extreme caution.
There were several reporting problems that made comparison
across the studies problematic. Korones failed to report frequency of
MRI imaging by tumor grade or type, thereby rendering a cross-study
comparison of the effect of differing imaging schedules on the rate of
asymptomatic recurrence for different tumor types impossible.7 Simi-
larly, Kornreich8 did not report patients by symptomatic status at time
of progression. Only Perreault9 reported patients and recurrences by
tumor typeand symptomatic status, enablingobservations tobedrawn
that could potentially inform the design of future trials. However, it is
important to appreciate that the data analyzed in these studies were
acquired for clinical purposes for which assessment of surveillance
imaging protocols was not an objective.
The initial aim of this review was to assess the effectiveness of
surveillance MRI. RCTs were required to do this, but as none were
found, the focus was switched to finding studies that were specif-
ically conducted to describe surveillance scanning. With just three
studies meeting the inclusion criteria, one criticism of this review that
emerged from the peer review process was that the cooperative trials
should have been hand-searched for information on surveillance. This
raises an interesting point about the best way to systematically review
pediatric oncology trials. Systematic reviewing (especially employing
Cochrane methodology) was developed with single-question trials
involving more common diseases in mind, i.e., A versus B, whereas
pediatric oncology trials tend to be cooperative, multimodal trials that
attempt to answer a variety of questionswithin a single trial due to the
rarity of thediseases. In response to thepeer review feedback, a search
of cooperative trials inmedulloblastomawas undertaken to determine
whether there were data within these trials to inform the review
question. Of 27 trials, surveillanceMRI scanning intervals appeared to
be arbitrary and variable, with few reasons given for the surveillance
schedules (see Supporting Information File S6). Only one study, not
identified in our systematic review searches likely due to indexing,
evaluated the number of patients who had relapse detected through
surveillanceMRI comparedwith symptom-based relapse.22 This study
reported that 45 relapses were detected on surveillance MRI, with
20 detected from symptoms alone. Of these, patients detected from
symptoms had a significantly shorter survival postrelapse than those
detected by surveillance MRI (P < 0.01), although OS postprimary
diagnosis was not statistically significantly different. This could be due
to lead time bias or that patients in the symptomatic relapse group
possibly have more aggressive tumors. Finding the evidence in a sys-
tematic way, from identifying the relevant publications to finding the
information within the trial publications (often results are written into
the discussions) can be challenging in these large cooperative trials. In
the future, we recommend that systematic reviewers consider hand-
searching relevant cooperative trials, while bearing in mind that the
main aimof these trialsmight differ from that of the systematic review.
Wealso urge authors of cooperative trials to improve the transparency
of their publications, especially with respect to database indexing as
well as signposting and organization of information within the
papers.
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The paucity of data evidenced in this review may be due to the
complexity of surveillance in these patients, with frequency of mon-
itoring depending on tumor type, disease status (newly diagnosed,
resistant or relapsed), extent of metastatic spread, and previous
treatments. Other factors such as pseudoprogression and radiation
necrosis can also complicate the interpretation of scans, making it a
difficult area to investigate. However, there is a need to examine this
question further in order to guide clinicians in developing optimal
evidence-based surveillance strategies, to help parents and children
understand the need for surveillance, and to optimize the use of
health service resources. There is a role for researchers to build into
future, large cooperative trials methodology that investigates the
role of surveillance MRI or, at the very minimum, collects and reports
data on the trial surveillance MRI practice, as well as incorporating
quality-of-life data collection, particularly regarding anxiety around
surveillance and the reassurance that it may also afford.
5 CONCLUSION
Only three retrospective observational studies with a high risk of bias
were identified to guide clinical practice of surveillance MRI for chil-
dren with high-grade CNS tumors.7–9 These studies do not clearly
demonstrate benefit or harm for this practice, nor do they define
methods or intervals for maximal effectiveness. To resolve this, more
research is neededwith the ultimate endpoints of surveillance relating
to survival and quality of life, as opposed to surrogate outcomes such
as the detection of tumor growth. As most of the patients within this
group are treated within the context of a cooperative clinical trial, this
research could be built into trial protocols for very little extra invest-
ment. It is an important question, not only to clinicians andpatients and
their families but also as a health service resource question.
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